Paragon Financial Partners’s Merck MRK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$370K Buy
3,083
+2
+0.1% +$231 0.21% 61
2025
Q4
$324K Buy
3,081
+1
+0% +$94 0.2% 60
2025
Q3
$258K Sell
3,080
-1
-0% -$82 0.16% 65
2025
Q2
$244K Buy
3,081
+1
+0% +$79 0.17% 64
2025
Q1
$276K Sell
3,080
-403
-12% -$37.6K 0.22% 61
2024
Q4
$347K Sell
3,483
-354
-9% -$36.5K 0.26% 53
2024
Q3
$436K Buy
3,837
+2
+0.1% +$238 0.32% 49
2024
Q2
$475K Buy
3,835
+2
+0.1% +$258 0.37% 44
2024
Q1
$506K Buy
3,833
+1
+0% +$123 0.42% 43
2023
Q4
$418K Buy
3,832
+2
+0.1% +$208 0.4% 47
2023
Q3
$394K Buy
3,830
+2
+0.1% +$216 0.41% 45
2023
Q2
$442K Buy
3,828
+101
+3% +$11.5K 0.42% 45
2023
Q1
$397K Buy
3,727
+2
+0.1% +$216 0.42% 51
2022
Q4
$413K Buy
3,725
+1
+0% +$102 0.46% 43
2022
Q3
$321K Buy
3,724
+2
+0.1% +$179 0.36% 52
2022
Q2
$339K Buy
3,722
+138
+4% +$12.2K 0.35% 53
2022
Q1
$294K Buy
3,584
+100
+3% +$7.88K 0.26% 67
2021
Q4
$267K Buy
+3,484
New +$277K 0.22% 75

Other funds holding MRK

Paragon Financial Partners's MRK Position: Q1 2026 in Review

Paragon Financial Partners increased its Merck (MRK) stake by 0.06% in Q1 2026, buying an estimated $231 and bringing the position to 3,083 shares worth $370K. The position accounts for 0.21% of the portfolio, ranked #61.

Paragon Financial Partners first reported a position in MRK in Q4 2021 and has held it in 18 quarters since. The position peaked at $506K in Q1 2024. 3,780 funds tracked by Wall St. Rank hold MRK as of Q1 2026.

  • Paragon Financial Partners held 3,083 shares of Merck worth $370K as of Q1 2026.
  • Paragon Financial Partners bought 2 Merck shares in Q1 2026, an estimated $231.
  • Merck made up 0.21% of Paragon Financial Partners's portfolio in Q1 2026, its #61 holding.
  • Paragon Financial Partners first reported a position in Merck in Q4 2021 and has held it in 18 quarters since.
  • Paragon Financial Partners's Merck position peaked at $506K in Q1 2024.
  • 3,780 funds tracked by Wall St. Rank held Merck as of Q1 2026.

Based on Paragon Financial Partners's 13F filing for Q1 2026, filed 17 Apr 2026.